Quantum Stem Cell Therapy for Recovery of Liver Disease

Authors

  • Deby Susanti Vinski Celltech Stem Cell Centre Laboratory and Banking, Jakarta, Indonesia
  • CA Schroeter Kastanienh of Clinic, Statthalterhofweg 70, D – 50858 KÖLN JUNKERSDORF, German
  • Marhaen Hardjo Universitas Hasanuddin, Sulawesi Selatan, Indonesia
  • Andi Kurniawan Nugroho Universitas Negeri Semarang, Jawa Tengah, Indonesia
  • Natasha Cinta Vinski Celltech Stem Cell Centre Laboratory and Banking, Jakarta, Indonesia

DOI:

https://doi.org/10.58344/jws.v3i5.609

Keywords:

Stem Cell, Liver Disease, Regenerative Medicine, Cell Therapy, Mesenchymal Stem Cell, Human Liver Liver Stem Cell

Abstract

Chronic liver diseases pose a significant global health challenge, necessitating the development of novel therapeutic strategies for liver regeneration and functional recovery. Mesenchymal stem cells (MSCs) derived from umbilical cord blood have emerged as promising candidates for liver regeneration due to their multipotent differentiation capacity, immunomodulatory properties, and paracrine effects. This study aims to investigate the efficacy, safety, and underlying mechanisms of stem cell therapy in the recovery and regeneration of liver tissue in patients with liver disease. The research method used is a case study where Mesenchymal Stem Cell therapy offers the potential to modify the natural recovery of Liver function using stem cell-based technology. Case studies were carried out on several Vinski Regenerative Center clinic patients. This review explores the therapeutic potential of umbilical cord blood-derived MSCs in promoting the recovery of liver function in preclinical and clinical settings. We discuss the mechanisms by which MSCs facilitate liver regeneration, including their ability to differentiate into hepatocyte-like cells, modulate immune responses, and secrete trophic factors that promote tissue repair. Preclinical studies demonstrate the efficacy of umbilical cord blood-derived MSCs in ameliorating liver injury, reducing fibrosis, and improving overall liver function. Challenges such as optimal dosing, timing of administration, and long-term monitoring remain to be addressed. Nevertheless, MSCs from umbilical cord blood represent a promising therapeutic approach for liver regeneration and hold great potential for improving outcomes in patients with liver disease.

References

Asrani, S. K., Devarbhavi, H., Eaton, J., & Kamath, P. S. (2019). The burden of liver diseases in the world. Journal of Hepatology, 70(1), 151–171.

Barouki, R., Samson, M., Blanc, E. B., Colombo, M., Zucman-Rossi, J., Lazaridis, K. N., Miller, G. W., & Coumoul, X. (2023). The exposome and liver disease environmental factors affect liver health. Journal of Hepatology, 79(2), 492–505.

Beier, J. I., & Arteel, G. E. (2021). Environmental exposure as a risk-modifying factor in liver diseases: Knowns and unknowns. Acta Pharmaceutica Sinica B, 11(12), 3768–3778.

Bell, B. P. (2022). Hepatitis A vaccine. Seminars in Pediatric Infectious Diseases, 13(3), 165–173.

Bhadoria, A. S., Mohapatra, A., Gupta, R., Chawla, Y. K., Kant, R., & Nundy, S. (2023). Preventive hepatology: An ounce of prevention or pounds of cure to curb liver diseases. In Journal of Family Medicine and Primary Care (Vol. 12, Issue 3, pp. 419–421). Medknow.

Bisteau, X., Caldez, M. J., & Kaldis, P. (2014). The complex relationship between liver cancer and the cell cycle: a story of multiple regulations. Cancers, 6(1), 79–111.

Butler, B., Narayan, B., Potts, J., & Emmanuel, J. (2016). Symptomatic acute hepatitis C infection following a single episode of unprotected sexual intercourse. Case Reports in Infectious Diseases, 2016.

Chisari, F. V, Isogawa, M., & Wieland, S. F. (2010). Pathogenesis of hepatitis B virus infection. Pathologie Biologie, 58(4), 258–266.

Cohen, P. R. (2021). Tattoo-associated viral infections: a review. Clinical, Cosmetic and Investigational Dermatology, 1529–1540.

Dolkar, T., Hamad, A. M., Han, M. M., Thu, M. B., Gayam, V. R., & Gayam, V. R. (2022). Cocaine and opioid-induced acute liver injury: a rare case report. Cureus, 14(3).

Fang, Y., Yu, J., Lou, J., Peng, K., Zhao, H., & Chen, J. (2021). Clinical and genetic spectra of inherited liver disease in children in China. Frontiers in Pediatrics, 9, 631620.

Flores, J. E., Thompson, A. J., Ryan, M., & Howell, J. (2022). The global impact of hepatitis B vaccination on hepatocellular carcinoma. Vaccines, 10(5), 793.

Francis, P., & Navarro, V. J. (2020). Drug-induced hepatotoxicity.

Gao, S., Jiang, X., Wang, L., Jiang, S., Luo, H., Chen, Y., & Peng, C. (2022). The pathogenesis of liver cancer and the therapeutic potential of bioactive substances. Frontiers in Pharmacology, 13, 1029601.

Guo, W., Ge, X., Lu, J., Xu, X., Gao, J., Wang, Q., Song, C., Zhang, Q., & Yu, C. (2022). Diet and risk of nonalcoholic fatty liver disease, cirrhosis, and liver cancer: a large prospective cohort study in UK Biobank. Nutrients, 14(24), 5335.

Hagan, H., Thiede, H., Weiss, N. S., Hopkins, S. G., Duchin, J. S., & Alexander, E. R. (2001). Sharing of drug preparation equipment as a risk factor for hepatitis C. American Journal of Public Health, 91(1), 42.

Han, Y., Li, X., Zhang, Y., Han, Y., Chang, F., & Ding, J. (2019). Mesenchymal stem cells for regenerative medicine. Cells, 8(8), 886.

Huang, J., Gao, T., Zhang, H., & Wang, X. (2023). Association of obesity profiles and metabolic health status with liver injury among US adult population in NHANES 1999–2016. Scientific Reports, 13(1), 15958.

Hussain, S. (2011). Patient counseling about herbal-drug interactions. African Journal of Traditional, Complementary and Alternative Medicines, 8(5S).

Iorio, N., & John, S. (2023). Hepatitis A. In StatPearls [Internet]. StatPearls Publishing.

Iqbal, H., Mehmood, B. F., Sohal, A., & Roytman, M. (2023). Hepatitis E infection: A review. World Journal of Virology, 12(5), 262.

Khalil, A., Quaglia, A., Gélat, P., Saffari, N., Rashidi, H., & Davidson, B. (2023). New Developments and Challenges in Liver Transplantation. Journal of Clinical Medicine, 12(17), 5586.

King, K. C., & Strony, R. (n.d.). Continued Education Activity.

Koenig, K. L., Shastry, S., & Burns, M. J. (2017). Hepatitis A virus: essential knowledge and a novel identify-isolate-inform tool for frontline healthcare providers. Western Journal of Emergency Medicine, 18(6), 1000.

Konkwo, C., Chowdhury, S., & Vilarinho, S. (2024). Genetics of liver disease in adults. Hepatology Communications, 8(4), e0408.

Künzler-Heule, P., Fierz, K., Schmidt, A. J., Rasi, M., Bogdanovic, J., Kocher, A., Engberg, S., Battegay, M., Nöstlinger, C., & Lehner, A. (2021). Response to a sexual risk reduction intervention provided in combination with hepatitis C treatment by HIV/HCV co-infected men who have sex with men: a reflexive thematic analysis. BMC Infectious Diseases, 21, 1–13.

Kushner, T. (2024). Introduction: Addressing patient-reported symptoms of chronic liver disease. In Clinical Liver Disease (Vol. 23, Issue 1, p. e0106). LWW.

Lang, A. L., & Beier, J. I. (2018). Interaction of volatile organic compounds and underlying liver disease: a new paradigm for risk. Biological Chemistry, 399(11), 1237–1248.

Li, H.-C., & Lo, S.-Y. (2015). Hepatitis C virus: Virology, diagnosis and treatment. World Journal of Hepatology, 7(10), 1377.

Linzay, C. D., Sharma, B., & Pandit, S. (2021). Autoimmune hepatitis.[Updated 2021 Aug 27]. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing.

Lopes, D., & Samant, H. (2021). StatPearls.

Luo, Y., & Lin, H. (2021). Inflammation initiates a vicious cycle between obesity and nonalcoholic fatty liver disease. Immunity, Inflammation and Disease, 9(1), 59–73.

Malaguarnera, G., Cataudella, E., Giordano, M., Nunnari, G., Chisari, G., & Malaguarnera, M. (2012). Toxic hepatitis in occupational exposure to solvents. World Journal of Gastroenterology: WJG, 18(22), 2756.

Mancak, M., Altintas, D., Balaban, Y., & Caliskan, U. K. (2024). Evidence-based herbal treatments in liver diseases. Hepatology Forum, 5(1), 50.

Manne, V., Ryan, J., Wong, J., Vengayil, G., Basit, S. A., & Gish, R. G. (2021). Hepatitis C vaccination: where we are and where we need to be. Pathogens, 10(12), 1619.

Masood, U., & John, S. (2017). Hepatitis D.

Mehta, P., & Reddivari, A. K. R. (2021). Hepatitis. StatPearls. StatPearls Publishing.

Moon, S. Y., Son, M., Kang, Y. W., Koh, M., Lee, J. Y., & Baek, Y. H. (2023). Alcohol consumption and the risk of liver disease: a nationwide, population-based study. Frontiers in Medicine, 10.

Nazarie, S.-R., Gharbia, S., Hermenean, A., Dinescu, S., & Costache, M. (2021). Regenerative potential of mesenchymal stem cells (MSCs) secretome for liver fibrosis therapies. International Journal of Molecular Sciences, 22(24), 13292.

Ni, Y. I., Lempp, F. A., Mehrle, S., Nkongolo, S., Kaufman, C., Fälth, M., Stindt, J., Königer, C., Nassal, M., & Kubitz, R. (2014). Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology, 146(4), 1070–1083.

Patel, R., Mueller, M., & Doerr, C. (2021). Alcoholic liver disease (nursing).

Pérez-Gracia, M. T., García, M., Suay, B., & Mateos-Lindemann, M. L. (2015). Current knowledge on hepatitis E. Journal of Clinical and Translational Hepatology, 3(2), 117.

Prince, D. S., Nash, E., & Liu, K. (2023). Alcohol-Associated Liver Disease: Evolving Concepts and Treatments. Drugs, 83(16), 1459–1474.

Roberts, H., Jiles, R., Harris, A. M., Gupta, N., & Teshale, E. (2021). Incidence and prevalence of sexually transmitted hepatitis B, United States, 2013–2018. Sexually Transmitted Diseases, 48(4), 305–309.

Romero-Gómez, M., Zelber-Sagi, S., Martín, F., Bugianesi, E., & Soria, B. (2023). Nutrition could prevent or promote nonalcoholic fatty liver disease: an opportunity for intervention. Bmj, 383.

Schonfeld, E. A., & Brown, R. S. (2019). Genetic causes of liver disease: when to suspect a genetic aetiology, initial lab testing, and management basics. Medical Clinics, 103(6), 991–1003.

Sen, P., Qadri, S., Luukkonen, P. K., Ragnarsdottir, O., McGlinchey, A., Jäntti, S., Juuti, A., Arola, J., Schlezinger, J. J., & Webster, T. F. (2022). Exposure to environmental contaminants is associated with altered hepatic lipid metabolism in nonalcoholic fatty liver disease. Journal of Hepatology, 76(2), 283–293.

Soleiman-Meigooni, S., Asgari, A., Hoseini-Shokouh, S. J., Rajabi, J., Kazemi-Galougahi, M. H., & Moshtaghi, M. (2015). Association between Hepatitis G and Unknown Chronic Hepatitis. Electronic Physician, 7(1), 985.

Spengler, U. (2020). Liver disease associated with non-hepatitis viruses. Encyclopedia of Gastroenterology, 363.

Thyfault, J. P., & Bergouignan, A. (2020). Exercise and metabolic health: beyond skeletal muscle. Diabetologia, 63(8), 1464–1474.

Tohme, R. A., & Holmberg, S. D. (2012). Transmission of hepatitis C virus infection through tattooing and piercing: a critical review. Clinical Infectious Diseases, 54(8), 1167–1178.

Wahlang, B., Beier, J. I., Clair, H. B., Bellis-Jones, H. J., Falkner, K. C., McClain, C. J., & Cave, M. C. (2013). Toxicant-associated steatohepatitis. Toxicologic Pathology, 41(2), 343–360.

Yang, S., Wang, D., Zhang, Y., Yu, C., Ren, J., Xu, K., Deng, M., Tian, G., Ding, C., & Cao, Q. (2015). Transmission of hepatitis B and C virus infection through body piercing: a systematic review and meta-analysis. Medicine, 94(47), e1893.

You, C. R., Lee, S. W., Jang, J. W., & Yoon, S. K. (2014). Update on hepatitis B virus infection. World Journal of Gastroenterology: WJG, 20(37), 13293.

Downloads

Published

2024-05-30

How to Cite

Susanti Vinski, D., Schroeter, C. ., Hardjo, M. ., Kurniawan Nugroho, A. ., & Cinta Vinski, N. . (2024). Quantum Stem Cell Therapy for Recovery of Liver Disease. Journal of World Science, 3(5), 541–556. https://doi.org/10.58344/jws.v3i5.609

Most read articles by the same author(s)